Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

This publication has 35 references indexed in Scilit:

• Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
  Journal of Clinical Oncology, 2006
• Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
  British Journal of Cancer, 2006
• Synergistic effects of docetaxel and S‐1 by modulating the expression of metabolic enzymes of 5‐fluorouracil in human gastric cancer cell lines
  International Journal of Cancer, 2006
• Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel
  Journal of Clinical Oncology, 2005
• Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803
  Journal of Clinical Oncology, 2004
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
  European Journal Of Cancer, 1998
• 1180: First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial
  European Journal Of Cancer, 1997
• Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
  British Journal of Cancer, 1995
• Optimal two-stage designs for phase II clinical trials
  Controlled Clinical Trials, 1989